Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: BRITAIN

Sector: Biotechnology

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1...
Website: centessa.com


  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -12.4% (LTM)
  • Share price is 308.6% higher than minimum and 34.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 0.0x)
  • For the last 3 months insiders bought company shares on $2.8 mln (0.262% of cap.)

Key Financials (Download financials)

Ticker: CNTA
Share price, USD:  (+2.8%)12.38
year average price 14.31  


year start price 10.18 2024-06-15

min close price 8.52 2024-06-18

max close price 19.03 2025-02-08

current price 12.38 2025-06-14
Common stocks: 94 040 998

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%

Target EV / EBITDA (hist percentile): 0.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 164
Net Debt ($m): -470
EV (Enterprise Value): 694
EBITDA LTM (млн $): -419
Price to Book: 2.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-04zacks.com

Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

2025-01-08globenewswire.com

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

2024-09-28marketbeat.com

Wake Up to This Biotech Stock That Still Has Big Potential Upside

2024-09-26globenewswire.com

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

2024-09-12globenewswire.com

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

2024-09-11globenewswire.com

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

2024-08-27globenewswire.com

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

2024-07-16zacks.com

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

2024-05-28zacks.com

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

2024-05-21globenewswire.com

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-10-18 2024-05-13 2024-03-28 2023-11-13 2023-08-14 2023-05-12 2023-03-30 2022-11-10 2022-08-10
acceptedDate 2024-11-12 07:16:41 2024-10-18 16:01:01 2024-05-13 16:32:10 2024-03-28 16:44:50 2023-11-13 16:22:34 2023-08-14 07:18:13 2023-05-12 07:14:36 2023-03-30 07:44:44 2022-11-10 07:09:10 2022-08-10 06:58:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 7M 0 0 0 0 0 0
costOfRevenue 0 236 264 239 862 248 139 236 618 237 762 0 0 0 0
grossProfit 0 -236 264 -239 862 7M -236 618 -237 762 0 0 0 0
grossProfitRatio 0 0 0 0.964 0 0 0 0 0 0
researchAndDevelopmentExpenses 34M 33M 23M 30M 28M 34M 33M 28M 37M 54M
generalAndAdministrativeExpenses 13M 11M 13M 12M 12M 13M 16M 14M 12M 15M
sellingAndMarketingExpenses 0 0 -247 537 -141 012 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 13M 11M 13M 12M 12M 13M 16M 14M 12M 15M
otherExpenses 0 0 -2M -878 000 -2M -2M -1M -70 000 0 0
operatingExpenses 46M 44M 36M 42M 40M 47M 49M 42M 49M 68M
costAndExpenses 46M 44M 36M 42M 40M 47M 49M 42M 49M 68M
interestIncome 3M 3M 3M 3M 3M 2M 3M 0 0 0
interestExpense 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M
depreciationAndAmortization 7M 236 000 239 862 248 139 238 000 237 000 1M -70 000 -3M 32 000
ebitda -39M -40M -36M -35M -39M -46M -48M -42M -52M -63M
ebitdaratio 0 0 0 -5.097 0 0 0 0 0 0
operatingIncome -46M -44M -36M -35M -40M -47M -49M -42M -49M -68M
operatingIncomeRatio 0 0 0 -5.133 0 0 0 0 0 0
totalOtherIncomeExpensesNet 4M 869 000 -1M -519 475 -2M -2M -1M -2M -5M 4M
incomeBeforeTax -42M -43M -38M -36M -41M -49M -50M -44M -54M -65M
incomeBeforeTaxRatio 0 0 0 -5.208 0 0 0 0 0 0
incomeTaxExpense 608 000 705 000 480 725 1M -3M -24M 677 000 -664 000 -141 000 -22 000
netIncome -43M -44M -38M -37M -39M -25M -51M -43M -54M -65M
netIncomeRatio 0 0 0 -5.375 0 0 0 0 0 0
eps -0.37 -0.4 -0.38 -0.38 -0.4 -0.26 -0.53 -0.46 -0.57 -0.69
epsdiluted -0.37 -0.4 -0.38 -0.38 -0.4 -0.26 -0.53 -0.46 -0.57 -0.69
weightedAverageShsOut 116M 109M 100M 98M 97M 95M 95M 95M 94M 94M
weightedAverageShsOutDil 116M 109M 100M 98M 97M 95M 95M 95M 94M 94M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-10-18 2024-05-13 2024-03-28 2023-11-13 2023-08-14 2023-05-12 2023-03-30 2022-11-10 2022-08-10
acceptedDate 2024-11-12 07:16:41 2024-10-18 16:01:01 2024-05-13 16:32:10 2024-03-28 16:44:50 2023-11-13 16:22:34 2023-08-14 07:18:13 2023-05-12 07:14:36 2023-03-30 07:44:44 2022-11-10 07:09:10 2022-08-10 06:58:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 395M 127M 118M 128M 171M 145M 260M 394M 445M 484M
shortTermInvestments 123M 167M 112M 129M 110M 158M 86M 0 0 0
cashAndShortTermInvestments 518M 295M 230M 257M 281M 304M 346M 394M 445M 484M
netReceivables 40M 47M 37M 39M 30M 28M 23M 27M 22M 22M
inventory 0 0 1 1 18M 15M 12M -30M 0 0
otherCurrentAssets 10M 14M 17M 19M 3M 4M 3M 3M 1M 14M
totalCurrentAssets 568M 356M 284M 315M 332M 350M 384M 394M 477M 519M
propertyPlantEquipmentNet 12M 12M 13M 13M 13M 13M 13M 1M 552 000 905 000
goodwill 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0
taxAssets 27M 29M 29M 32M 30M 27M 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 3M 2M 2M 6M 49M 2M 648 000
totalNonCurrentAssets 41M 43M 44M 48M 45M 43M 20M 51M 2M 2M
otherAssets 0 0 0 0 0 0 0 0 0 0
totalAssets 610M 399M 328M 363M 377M 393M 404M 444M 479M 521M
accountPayables 7M 5M 7M 12M 11M 11M 14M 14M 11M 8M
shortTermDebt 577 000 552 000 528 000 0 482 000 460 000 398 000 0 0 0
taxPayables 0 0 0 112 000 0 0 2M 2M 0 0
deferredRevenue 0 0 0 0 23M 22M 0 0 0 0
otherCurrentLiabilities 18M 21M 19M 28M 159 000 507 000 15M 25M 27M 25M
totalCurrentLiabilities 26M 27M 27M 39M 35M 34M 30M 38M 38M 34M
longTermDebt 84M 85M 77M 76M 83M 82M 81M 70M 68M 67M
deferredRevenueNonCurrent 0 0 0 9M 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 3M 0 0 0 0 0 0
otherNonCurrentLiabilities 29 000 29 000 9M 29 000 0 0 0 38M 57M 43 000
totalNonCurrentLiabilities 84M 85M 86M 87M 83M 82M 81M 108M 68M 67M
otherLiabilities 0 0 0 0 0 0 0 -38M 0 0
capitalLeaseObligations 577 000 9M 9M 9M 10M 10M 10M 0 0 0
totalLiabilities 111M 112M 113M 127M 118M 116M 111M 108M 106M 101M
preferredStock 0 0 0 0 0 0 0 0 0 0
commonStock 357 000 309 000 277 000 273 000 271 000 266 000 266 000 265 000 263 000 263 000
retainedEarnings -877M -835M -791M -753M -716M -677M -653M -602M -559M -505M
accumulatedOtherComprehensiveIncomeLoss 2M 2M 2M 1M 779 000 946 000 -599 000 -1M -2M -1M
othertotalStockholdersEquity 1 374M 1 120M 1 004M 987M 974M 953M 946M 939M 933M 926M
totalStockholdersEquity 499M 287M 215M 236M 259M 277M 293M 336M 373M 420M
totalEquity 499M 287M 215M 236M 259M 277M 293M 336M 373M 420M
totalLiabilitiesAndStockholdersEquity 610M 399M 328M 363M 377M 393M 404M 444M 479M 521M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 610M 399M 328M 363M 377M 393M 404M 444M 479M 521M
totalInvestments 123M 167M 112M 129M 110M 158M 86M 0 0 0
totalDebt 85M 86M 86M 85M 84M 83M 81M 70M 68M 67M
netDebt -310M -42M -32M -43M -88M -62M -179M -324M -377M -417M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-10-18 2024-05-13 2024-03-28 2023-11-13 2023-08-14 2023-05-12 2023-03-30 2022-11-10 2022-08-10
acceptedDate 2024-11-12 07:16:41 2024-10-18 16:01:01 2024-05-13 16:32:10 2024-03-28 16:44:50 2023-11-13 16:22:34 2023-08-14 07:18:13 2023-05-12 07:14:36 2023-03-30 07:44:44 2022-11-10 07:09:10 2022-08-10 06:58:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -43M -44M -38M -37M -39M -25M -51M -43M -54M -65M
depreciationAndAmortization 236 000 236 000 239 862 248 139 238 000 237 000 89 000 36 000 35 000 32 000
deferredIncomeTax 1M 567 000 433 752 -135 328 -3M -24M 0 -3M 0 0
stockBasedCompensation 8M 9M 8M 7M 8M 7M 7M 7M 7M 6M
changeInWorkingCapital 12M -6M -9M -3M -4M -6M -5M -14M 7M 6M
accountsReceivables 10M 0 1M -8M -2M -6M 0 0 0 0
inventory 0 0 0 1 2M 6M 0 0 0 0
accountsPayables 2M -2M -4M 590 058 83 000 -2M -2M 3M 3M 2M
otherWorkingCapital 255 000 -4M -6M 4M -5M -4M 2M -17M 4M 0
otherNonCashItems -570 000 -290 051 13M 2M 795 000 3M 975 000 2M 665 000 -7M
netCashProvidedByOperatingActivities -21M -41M -37M -31M -37M -44M -48M -52M -39M -60M
investmentsInPropertyPlantAndEquipment -34 001 1.551 0 -28 032 -43 000 -10000 -88 000 -652 000 -16 000 -229 000
acquisitionsNet 0 0 0 18M -87M 0 0 0 0 0
purchasesOfInvestments 147M -121M -20M -70M -37M -71M -86M 0 0 0
salesMaturitiesOfInvestments 45M 65M 37M 52M 87M 0 0 0 0 0
otherInvestingActivites -147M -52 905 17M -18M 86M 0 0 206 000 0 0
netCashUsedForInvestingActivites 45M -55M 17M -18M 49M -71M -86M -446 000 -16 000 -229 000
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 243M 107M 10M 6M 15M 12 075 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M -2M 10M 6M -65 089 -75 0 89 000 224 000 70 000
netCashUsedProvidedByFinancingActivities 246M 105M 10M 6M 15M 12 000 0 89 000 224 000 70 000
effectOfForexChangesOnCash -2M -120 000 219 000 -504 000 220 000 381 000 518 000 722 000 -438 000 -268 000
netChangeInCash 268M 9M -10M -43M 26M -115M -134M -51M -39M -60M
cashAtEndOfPeriod 395M 127M 118M 128M 171M 145M 260M 394M 445M 484M
cashAtBeginningOfPeriod 127M 118M 128M 171M 145M 260M 394M 445M 484M 544M
operatingCashFlow -21M -41M -37M -31M -37M -44M -48M -52M -39M -60M
capitalExpenditure -34 001 1.551 0 -28 032 -43 000 -10000 -88 000 -652 000 -16 000 -229 000
freeCashFlow -21M -41M -37M -31M -37M -44M -48M -52M -39M -60M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-12 12:00 ET
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
2024-11-12 12:00 ET
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
2024-11-04 12:30 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-09-26 10:00 ET
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
2024-09-11 20:04 ET
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
2024-09-11 20:04 ET
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
2024-09-10 11:00 ET
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
2024-09-10 11:00 ET
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
2024-08-27 12:00 ET
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
2024-08-27 12:00 ET
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
2024-08-21 12:00 ET
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-13 11:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
2024-08-13 11:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
2024-06-10 11:00 ET
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
2024-05-30 06:35 ET
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
2024-05-21 12:45 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-05-13 20:10 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
2024-05-13 20:10 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
2024-04-24 01:36 ET
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
2024-04-24 01:36 ET
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
2024-04-24 01:36 ET
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
2024-04-24 01:36 ET
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
2024-04-23 20:17 ET
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
2024-04-23 20:17 ET
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
2024-04-23 20:17 ET
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
2024-04-23 20:17 ET
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
2024-04-22 11:00 ET
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
2024-04-22 11:00 ET
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
2024-03-28 20:28 ET
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
2024-03-28 20:28 ET
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
2024-02-22 13:00 ET
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
2024-02-09 12:00 ET
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia...
2024-01-22 13:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-12-13 13:00 ET
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
2023-12-10 17:05 ET
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
2023-12-10 17:05 ET
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
2023-11-27 21:15 ET
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
2023-11-13 21:05 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
2023-11-13 21:05 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
2023-11-02 13:09 ET
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
2023-10-31 12:00 ET
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
2023-10-30 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-10-25 12:00 ET
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
2023-10-25 12:00 ET
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
2023-10-03 12:00 ET
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
2023-08-31 12:00 ET
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-23 21:08 ET
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
2023-08-14 11:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
2023-08-14 11:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
2023-07-10 12:00 ET
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
2023-07-10 12:00 ET
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
2023-05-24 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-05-24 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-05-22 11:00 ET
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
2023-05-22 11:00 ET
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
2023-05-12 11:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
2023-05-12 11:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
2023-03-30 11:00 ET
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
2023-03-30 11:00 ET
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
2023-03-27 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-03-27 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-03-23 20:30 ET
Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director
2023-03-01 13:00 ET
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
2023-03-01 13:00 ET
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
2023-02-06 13:00 ET
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
2023-02-06 13:00 ET
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
2023-02-02 13:00 ET
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
2023-02-02 13:00 ET
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
2023-01-26 14:08 ET
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
2023-01-26 14:08 ET
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
2022-12-10 20:30 ET
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
2022-12-10 20:30 ET
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
2022-11-30 13:00 ET
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
2022-11-30 13:00 ET
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
2022-11-10 20:20 ET
Centessa Pharmaceuticals Facing Investigation by National Securities Law Firm Over Alleged Misleading Statements
2022-11-10 12:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
2022-11-10 12:00 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
2022-11-03 13:04 ET
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting 
2022-11-03 13:04 ET
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting 
2022-10-31 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-10-31 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-09-20 12:33 ET
Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
2022-09-20 12:33 ET
Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)
2022-09-14 13:00 ET
Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
2022-09-14 13:00 ET
Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
2022-09-12 11:00 ET
Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index
2022-09-12 11:00 ET
Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index
2022-08-29 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-08-29 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-08-10 10:30 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
2022-08-10 10:30 ET
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
2022-07-25 12:00 ET
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
2022-07-25 12:00 ET
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
2022-07-18 10:00 ET
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
2022-07-01 12:40 ET
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
2022-07-01 12:40 ET
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
2022-06-06 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-06-06 12:00 ET
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
2022-06-05 11:00 ET
Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
2022-06-05 11:00 ET
Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
2022-06-02 10:29 ET
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2022-06-02 10:29 ET
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2022-05-16 11:00 ET
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates
2022-05-16 11:00 ET
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates
2022-03-30 20:01 ET
Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
2022-03-30 20:01 ET
Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
2022-03-23 20:30 ET
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
2022-03-23 20:30 ET
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
2022-03-07 12:30 ET
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
2022-03-07 12:30 ET
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
2022-02-24 12:30 ET
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
2022-02-24 12:30 ET
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
2021-12-14 12:30 ET
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Appli...
2021-12-14 12:30 ET
Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Appli...
2021-12-13 21:15 ET
Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
2021-12-13 21:15 ET
Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index
2021-11-15 12:00 ET
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
2021-11-15 12:00 ET
Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates
2021-11-10 21:45 ET
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
2021-11-10 21:45 ET
Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021
2021-11-01 11:30 ET
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
2021-11-01 11:30 ET
Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874
2021-10-18 12:00 ET
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
2021-10-18 12:00 ET
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
2021-10-18 12:00 ET
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists
2021-10-05 12:00 ET
Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
2021-10-05 12:00 ET
Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
2021-10-04 12:00 ET
Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital
2021-10-04 12:00 ET
Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital
2021-09-09 11:30 ET
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
2021-09-09 11:30 ET
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
2021-09-01 20:15 ET
Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
2021-09-01 20:15 ET
Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
2021-08-16 11:00 ET
Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates
2021-06-07 20:15 ET
Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-06-07 20:15 ET
Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-06-07 08:00 ET
Citi Appointed as Depositary Bank for Centessa Pharmaceuticals plc’s ADR Programme
2021-06-04 20:15 ET
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
2021-06-04 20:15 ET
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

SEC forms

Show financial reports only

SEC form 10
2025-05-14 00:00 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 10
2025-03-24 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 8
2025-03-24 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 8
2025-03-24 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 10
2024-11-12 07:16 ET
Centessa Pharmaceuticals plc reported for 2024 q3
SEC form 8
2024-11-12 07:08 ET
Centessa Pharmaceuticals plc published news for 2024 q3
SEC form 8
2024-11-12 07:08 ET
Centessa Pharmaceuticals plc published news for 2024 q3
SEC form 8
2024-11-12 07:08 ET
Centessa Pharmaceuticals plc published news for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Centessa Pharmaceuticals plc reported for 2024 q3
SEC form 10
2024-08-13 07:27 ET
Centessa Pharmaceuticals plc reported for 2024 q2
SEC form 8
2024-08-13 07:15 ET
Centessa Pharmaceuticals plc published news for 2024 q2
SEC form 8
2024-08-13 07:15 ET
Centessa Pharmaceuticals plc published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Centessa Pharmaceuticals plc reported for 2024 q2
SEC form 10
2024-05-13 16:32 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 8
2024-05-13 16:23 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 8
2024-05-13 16:23 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 10
2024-03-28 16:44 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 8
2024-03-28 16:35 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 8
2024-03-28 16:35 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 10
2023-11-13 16:22 ET
Centessa Pharmaceuticals plc reported for 2023 q3
SEC form 8
2023-11-13 16:17 ET
Centessa Pharmaceuticals plc published news for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q3
SEC form 10
2023-08-14 07:18 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 6
2023-08-14 07:06 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 6
2023-07-10 17:00 ET
Centessa Pharmaceuticals plc published news for 2023 q2
SEC form 6
2023-06-23 17:01 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-06-22 16:05 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-05-15 08:01 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 10
2023-05-12 07:14 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 6
2023-05-12 07:04 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 8
2023-05-12 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 6
2023-04-04 17:05 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:04 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:04 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:03 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:03 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:03 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:02 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:01 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 10
2023-03-30 07:44 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 6
2023-03-30 07:19 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 10
2023-03-30 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 6
2023-01-27 17:14 ET
Centessa Pharmaceuticals plc published news for 2022 q4
SEC form 6
2023-01-26 11:28 ET
Centessa Pharmaceuticals plc published news for 2022 q4
SEC form 6
2022-12-23 16:27 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-12-12 06:37 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-12-05 16:39 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 10
2022-11-10 07:09 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 6
2022-11-10 07:04 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 6
2022-10-14 07:00 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-10-06 17:06 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-09-12 07:16 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 10
2022-08-10 06:58 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 6
2022-08-10 06:45 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 6
2022-07-08 16:32 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 6
2022-07-06 18:00 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 6
2022-07-01 08:45 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 6
2022-06-30 16:34 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 6
2022-06-02 06:33 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 6
2022-05-23 08:00 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 10
2022-05-16 07:41 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 6
2022-05-16 07:14 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q1
SEC form 6
2022-05-02 16:30 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 10
2022-03-30 16:09 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-03-30 16:06 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-03-15 17:30 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-03-14 07:38 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-02-24 07:37 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-02-16 16:15 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-02-11 21:59 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2021-12-14 07:58 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 10
2021-11-15 07:13 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-11-15 07:11 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Centessa Pharmaceuticals plc published news for
SEC form 8
2021-11-15 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-11-01 07:38 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-10-08 18:00 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-10-04 08:07 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-09-09 07:34 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 10
2021-08-16 07:07 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 6
2021-08-16 07:05 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 6
2021-07-06 19:00 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 6
2021-05-27 20:34 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:32 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:32 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:31 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:31 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:30 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:26 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:26 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:25 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:25 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:24 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:23 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:22 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:20 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:20 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:20 ET
Centessa Pharmaceuticals plc published news for 2021 q1